BC
BML Capital Management, LLC
13F filer · CIK 0001616824Reported Aug 7, 2026
Net seller this quarter
13F portfolio value$176MU.S. long equity reported on 13F
Positions151 new · 1 closed
Net flow last quarter-$5.38MBuys minus sells
Top 10 positions weight93.3%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 7, 202615 positions | |||||
| $63.3M | 35.98% | 8.56% | -16.0% | Q4 2023 | |
| $32.3M | 18.36% | 8.67% | -1.5% | Q2 2023 | |
| $11.5M | 6.55% | 9.96% | New | Q2 2026 | |
| $11M | 6.24% | 0.04% | +272.0% | Q1 2026 | |
| $10.9M | 6.18% | 13.40% | +32.5% | Q4 2025 | |
| $9.12M | 5.18% | 0.12% | +11.3% | Q4 2025 | |
| $9.03M | 5.13% | 17.95% | Not reported | Q4 2022 | |
| $7.14M | 4.06% | 9.97% | +0.2% | Q1 2024 | |
| $4.96M | 2.82% | 9.52% | Not reported | Q1 2024 | |
| $4.9M | 2.78% | 0.01% | Not reported | Q3 2025 | |
| $4.17M | 2.37% | 2.10% | -72.7% | Q1 2023 | |
| $2.38M | 1.35% | 0.25% | Not reported | Q1 2026 | |
| $1.76M | 1.00% | 2.50% | Not reported | Q4 2025 | |
| $1.36M | 0.78% | 0.91% | +40.2% | Q4 2023 | |
| $1.18M | 0.67% | 1.78% | Not reported | Q3 2025 | |
| Q1 2026Reported May 6, 202615 positions | |||||
| $53.4M | 34.31% | 10.20% | Not reported | Q4 2023 | |
| $38M | 24.38% | 8.82% | -5.8% | Q2 2023 | |
| $10.8M | 6.91% | 7.74% | Not reported | Q1 2023 | |
| $8.71M | 5.59% | 17.95% | Not reported | Q4 2022 | |
| $7.3M | 4.69% | 10.27% | +250.2% | Q4 2025 | |
| $6.6M | 4.24% | 9.98% | +0.5% | Q1 2024 | |
| $6.44M | 4.14% | 0.11% | Not reported | Q4 2025 | |
| KLKZRKezar Life Sciences, Inc. | $5.35M | 3.43% | 9.77% | Not reported | Q4 2024 |
| $5.32M | 3.42% | 9.52% | Not reported | Q1 2024 | |
| $4.55M | 2.92% | 0.01% | Not reported | Q3 2025 | |
| $2.81M | 1.80% | 0.01% | New | Q1 2026 | |
| $2.15M | 1.38% | 0.25% | New | Q1 2026 | |
| $1.95M | 1.25% | 2.50% | Not reported | Q4 2025 | |
| $1.07M | 0.69% | 0.65% | Not reported | Q4 2023 | |
| $1M | 0.64% | 1.80% | +13.4% | Q3 2025 | |
| Q4 2025Reported Feb 3, 202613 positions | |||||
| $42.9M | 37.08% | 11.83% | Not reported | Q4 2023 | |
| $26.7M | 23.11% | 9.59% | +0.2% | Q2 2023 | |
| $9.03M | 7.80% | 8.06% | Not reported | Q1 2023 | |
| $7.1M | 6.14% | 9.52% | Not reported | Q1 2024 | |
| $6.62M | 5.72% | 9.92% | Not reported | Q1 2024 | |
| $5.99M | 5.18% | 0.11% | New | Q4 2025 | |
| KLKZRKezar Life Sciences, Inc. | $4.53M | 3.92% | 9.83% | Not reported | Q4 2024 |
| $3.67M | 3.17% | 0.01% | +275.0% | Q3 2025 | |
| $2.02M | 1.74% | 2.99% | New | Q4 2025 | |
| $1.89M | 1.63% | 2.52% | New | Q4 2025 | |
| $1.22M | 1.06% | 1.58% | -3.0% | Q3 2025 | |
| $1.15M | 1.00% | 0.72% | -67.7% | Q4 2023 | |
| $136K | 0.12% | 0.83% | -33.2% | Q4 2022 | |
| Q3 2025Reported Nov 10, 202518 positions | |||||
| $27.1M | 24.79% | 13.15% | Not reported | Q4 2023 | |
| $21.7M | 19.85% | 9.57% | -1.8% | Q2 2023 | |
| ABADVMAdverum Biotechnologies, Inc. | $13.9M | 12.68% | 14.57% | Not reported | Q4 2022 |
| $11.5M | 10.56% | 9.52% | +20.7% | Q1 2024 | |
| $8.36M | 7.66% | 7.76% | +2.7% | Q1 2023 | |
| $7.41M | 6.78% | 9.99% | +5.8% | Q1 2024 | |
| $4.83M | 4.42% | Not reported | Not reported | Q1 2025 | |
| LTLVTXLAVA Therapeutics NV | $3.07M | 2.81% | 7.49% | Not reported | Q1 2025 |
| KLKZRKezar Life Sciences, Inc. | $2.81M | 2.57% | 9.84% | +13.5% | Q4 2024 |
| $1.91M | 1.75% | 2.27% | -30.4% | Q4 2023 | |
| $1.49M | 1.36% | 4.54% | New | Q3 2025 | |
| $1.34M | 1.22% | 8.19% | New | Q3 2025 | |
| $1.08M | 0.99% | 12.53% | Not reported | Q4 2022 | |
| $897K | 0.82% | 0.00% | New | Q3 2025 | |
| $533K | 0.49% | 0.49% | Not reported | Q3 2023 | |
| $426K | 0.39% | 0.07% | New | Q3 2025 | |
| $288K | 0.26% | 1.25% | -47.7% | Q4 2022 | |
| MOMURAMural Oncology plc | $119K | 0.11% | 0.33% | New | Q3 2025 |
Premium opens every quarter this fund has filed